| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于活性试剂向细胞的递送的多价RNA纳粒 | CN200680036523.5 | 2006-08-01 | CN101292033A | 2008-10-22 | 郭培宣 |
| 由多个嵌合pRNA分子形成的多价多聚复合物，各携带至少一个生物学活性部分、可检测标记或其他异源组件。 | ||||||
| 2 | 用于活性试剂向细胞的递送的多价RNA纳粒 | CN200680036523.5 | 2006-08-01 | CN101292033B | 2013-04-03 | 郭培宣 |
| 由多个嵌合pRNA分子形成的多价多聚复合物，各携带至少一个生物学活性部分、可检测标记或其他异源组件。 | ||||||
| 3 | Prna Chimera | US10539241 | 2003-12-16 | US20080064647A1 | 2008-03-13 | Peixuan Guo; Stephen M. Hoeprich; Dan Shu |
| A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety. | ||||||
| 4 | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states | US09739843 | 2000-12-20 | US06893829B2 | 2005-05-17 | Jerry L. Nadler; Rama Natarajan |
| The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics. | ||||||
| 5 | Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells | US10688676 | 2003-10-17 | US20040248794A1 | 2004-12-09 | John M. Yanni; Daniel A. Gamache; Steven T. Miller |
| The present invention provides compositions comprising the 15-lipoxygenase-1 (15-LO-1) or 15-lipoxyngenase-2 (15-LO-2) gene such that 15-LO-1 or 15-LO-2 protein expression is replaced or replenished in the ocular surface epithelium of postmenopausal women suffering from dry eye. Thus, methods for treatment of dry eye in postmenopausal women are further provided. | ||||||
| 6 | JPH07500254A - | JP50734194 | 1993-08-26 | JPH07500254A | 1995-01-12 | |
| 7 | Polyhydric rna nanoparticles for the delivery of active agents to cells | JP2008525085 | 2006-08-01 | JP2009502198A | 2009-01-29 | グオ，ペイクスアン |
| 多数のキメラpRNA分子から形成された多価の多重結合性複合体であって、各々は、少なくとも1つの生物活性部分、検出可能な標識、又は他の異種成分を有する、前記複合体。 | ||||||
| 8 | pRNA chimera | US10373612 | 2003-02-24 | US07655787B2 | 2010-02-02 | Peixuan Guo; Stephen M. Hoeprich; Dan Shu |
| A circularly permuted chimeric pRNA molecule carrying a stabilized biologically active RNA, such as a ribozyme. | ||||||
| 9 | pRNA chimera | US12156514 | 2008-06-02 | US20080261277A1 | 2008-10-23 | Peixuan Guo; Stephen M. Hoeprich; Dan Shu |
| A circularly permuted chimeric pRNA molecule carrying a stabilized biologically active RNA, such as a ribozyme. | ||||||
| 10 | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states | US09739843 | 2000-12-20 | US20010009900A1 | 2001-07-26 | Jerry L. Nadler; Rama Natarajan |
| The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics. | ||||||
| 11 | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states | US08945744 | 1997-11-03 | US06191169B1 | 2001-02-20 | Jerry L. Nadler; Rama Natarajan |
| The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics. | ||||||
| 12 | pRNA chimera | US10539241 | 2003-12-16 | US08088912B2 | 2012-01-03 | Peixuan Guo; Stephen M. Hoeprich; Dan Shu |
| A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety. | ||||||
| 13 | Multivalent rna nanoparticles for delivery of active agents to a cell | US11989590 | 2006-08-01 | US20100003753A1 | 2010-01-07 | Peixuan Guo |
| A polyvalent multimeric complex formed from a plurality of chimeric pRNA molecules, each carrying at least one biologically active moiety, detectable label, or other heterologous component. | ||||||
| 14 | Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells | US10539093 | 2003-10-17 | US20060217325A1 | 2006-09-28 | John Yanni; Daniel Gamache; Steven Miller |
| The present invention provides compositions comprising the 15-lipoxygenase-1 (15-LO-1) or 15-lipoxyngenase-2 (15-LO-2) gene such that 15-LO-1 or 15-LO-2 protein expression is replaced or replenished in the ocular surface epithelium of post-menopausal women suffering from dry eye. Thus, methods for treatment of dry eye in postmenopausal women are further provided. | ||||||
| 15 | PRNA chimera | US10373612 | 2003-02-24 | US20040126771A1 | 2004-07-01 | Peixuan Guo; Stephen M. Hoeprich; Dan Shu |
| A circularly permuted chimeric pRNA molecule carrying a stabilized biologically active RNA, such as a ribozyme. | ||||||
| 16 | Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states | US09691845 | 2000-10-18 | US06486181B1 | 2002-11-26 | Jerry L. Nadler; Rama Natarajan |
| The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to inhibit disease etiology, to inhibit the proliferation of breast cancer and to increase insulin receptor phosphorylation in a patient having Type II diabetics. | ||||||
| 17 | pRNA chimera | EP10013183.8 | 2003-12-16 | EP2325313A3 | 2014-04-09 | Guo, Peixuan; Shu, Dan; Hoeprich, Stephen M. |
The present invention relates to a chimeric pRNA monomer that is selected from: (a) a chimeric pRNA monomer comprising a siRNA; (b) a chimeric pRNA monomer comprising a biologically active moiety at at least one of the 5' or the 3' end; and (c) a chimeric pRNA monomer comprising a 3' end annealed to an oligonucleotide. |
||||||
| 18 | PRNA CHIMERA | EP01964371.7 | 2001-08-23 | EP1366151B1 | 2007-10-24 | GUO, Peixuan; HOEPRICH, Stephen, M.; SHU, Dan |
| A circularly permuted chimeric PRNA molecule carrying a stabilized biologically active RNA, such as a ribozyme. | ||||||
| 19 | INHIBITION OF THE FORMATION OR ACTIVITY OF HUMAN LEUKOCYTE 12-LIPOXYGENASE PATHWAY | EP93921232.0 | 1993-08-26 | EP0621895A1 | 1994-11-02 | NADLER, Jerry, L.; NATARAJAN, Rama, Devi; GU, Jiali |
| L'invention concerne la découverte d'une nouvelle forme d'ARN de 12-lipoxygénase et d'une protéine dans les muscles lisses vasculaires, mononucléés, surrénaux et dans les cellules endothéliales de l'homme. L'activation de ce processus 12-LO régule l'angiotensine II et les activités rénales et vasculaires induites par le glucose. L'invention justifie le développement des procédés pharmaceutiques ou moléculaires permettant d'inhiber le processus de la lipoxygénase récemment découvert. | ||||||
| 20 | pRNA CHIMERA | EP03816665.8 | 2003-12-16 | EP1573070A2 | 2005-09-14 | GUO, Peixuan; HOEPRICH, Stephen, M.; SHU, Dan |
| A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety. | ||||||
QQ群二维码
意见反馈
意见反馈